Reducing patient burden in rare disease trials: DCTs for increased patient centricity
Reducing patient burden in clinical trials – especially for rare diseases – is a key objective for drug developers. Decentralized…
All articles by
-
-
Overcoming challenges in orphan drug development: From clinical trials to market
Developing treatments for rare diseases, known as orphan drugs, presents a range of unique challenges from the outset, from limited…
-
How collaborative partnerships are driving progress in transformative cell and gene therapies (CGTs)
Cell and gene therapies (CGTs) are currently at the heart of dynamic trends in the pharma sector. While oncology remains…
-
Obesity-related liver conditions: Understanding treatment options
The prevalence of obesity has more than doubled since 1990, with nearly one billion people living with obesity globally in…
-
Unmatched quality in pharmaceutical logistics: Why it matters
Ensuring the integrity of pharmaceutical products is one of the most complex challenges in global healthcare today. From temperature-sensitive biologics…
-
Artificial intelligence is making clinical supply chains more efficient and more sustainable: here’s how
The pharmaceutical industry is in the midst of a digital revolution; technology investments and data-driven decision-making are constantly on the…
-
How CNS researchers are handling clinical trial turbulence
The field of central nervous system (CNS) drug development is awash with activity. Data from GlobalData’s drugs database, as of…
-
Navigating the complexities of sustainable specialty pharma supply chains
The pharmaceutical world is changing. Sales of personalised therapies, for example, will skyrocket from $8 billion in 2022 to a…
-
Revolutionary approaches to drug design: how AI is transforming life sciences
With 2025 well underway, the runaway momentum of artificial intelligence (AI) looks unstoppable. GlobalData estimates that the total AI market…
-
Immunotherapeutic responses and their assessments
Immunotherapeutics have transformed the landscape of cancer outcomes. It is crucial that the atypical response patterns seen with them are…